Caroline Robert, MD, PhD

Articles

Dr. Robert on Potential of Dabrafenib/Trametinib in Melanoma Brain Metastases

September 6th 2019

Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussey, co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, explains why patients with melanoma and brain metastases were excluded from a trial evaluating the efficacy of dabrafenib plus trametinib.

Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma

June 4th 2019

Caroline Robert, MD, PhD, head of the Dermatology Unit in Gustave Roussy Cancer Center, Villejuif-Paris, France, discusses results of a 5-year analysis evaluating the long-term effects of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Dr. Robert on Next Steps Following the Phase III COMBI-v Study in Melanoma

October 14th 2016

Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the next steps following the results of the phase III COMBI-v study in BRAF-mutant melanoma.

Dr. Robert on the Phase III COMBI-v Study in BRAF-Mutant Melanoma

October 8th 2016

Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the results of the phase III COMBI-v study in BRAF-mutant melanoma during an interview at the ESMO 2016 Congress.

Dr. Robert on the Trametinib METRIC Trial Results

June 4th 2012

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

x